Booster Vaccination Study to Assess Immunogenicity and Safety of a Dose of GSK Biologicals Mencevax ACWY and 1/5th of a Dose of Mencevax ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study [EXTENSION OF 700037923].

Trial Profile

Booster Vaccination Study to Assess Immunogenicity and Safety of a Dose of GSK Biologicals Mencevax ACWY and 1/5th of a Dose of Mencevax ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study [EXTENSION OF 700037923].

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix) (Primary) ; Meningococcal vaccine groups A C W-135 polysaccharide; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top